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Interaction of tetraspanin KAI1/CD82 and tetraspanin CD151 in hepatocyte 
growth factor c-Met receptor regulation in prostate cancer cell lines
presence and absence of  CD82. The 
results indicate that the overexpression of  
CD82 in a metastatic prostate cancer cell 
line significantly reduces the association 
and regulation between CD151 and 
C-met and thus inhibits metastasis at the 
molecular level. The effectiveness of  the 
study was tested using two techniques 
that measure the changes in protein level 
expression called immunofluorescent 
staining and gel electrophoresis. 
Immunofluorescent staining allows for 
the protein expression on the cell surface 
to be visualized through fluorescent 
biomarkers. Three separate sets of  two 
proteins were stained with antibodies to 
be evaluated through immunofluorescent 
staining. Set 1: CD82 with C-met; 
Set 2: CD151 with C-met; and Set 3: 
CD82 with CD151, cellular surface 
expressions were studied. Understanding 
the relationship between these three 
proteins propose a greater potential 
for understanding the mechanism of  
metastasis. Analysis of  the specific 
molecules contributing to metastasis 
could orchestrate the development of  
successful targeted drug therapies as 
treatment for cancer. The uniqueness of  
this study allows for other researchers to 
piece the discovered information with 
known information to create a broader 
understanding in the field of  cancer 
biology. 
Cancer is a complex disease that 
is not well understood and alarmingly, 
according to a recent UK study published 
in 2015 in the British Journal of  Cancer, 
one in two people will be diagnosed with 
the tragic disease. Understanding the 
types and stages of  cancer leads the way 
toward generating effective and efficient 
treatments. The goals of  standard 
cancer treatments today are incredibly 
aggressive in order to rid the body of  
the cancerous cells. These forms of  
treatment initially appear ideal; however, 
after further investigation, those methods 
come with unforeseen consequences 
and do not take other factors into 
consideration. In order for a treatment 
plan to be successful, it must deviate 
from the “one size fits all” mentality 
and consider the fact that cancer varies 
with each individual in regard to genetic 
mutations, specific protein expression, 
severity, location, type and etiology of  
the disease. Today’s standard treatment 
methods include surgery, chemotherapy, 
radiation and immunotherapy. A problem 
that is common in patients receiving 
these aggressive treatments is that their 
healthy cells are compromised causing 
adverse effects. The least recognized 
yet potentially the most effective of  
all methods is targeted drug therapy. 
Targeted drug therapies work by 
attacking specific cellular signals used by 
cancer to spread, grow and communicate 
without affecting healthy cells. For 
example, through previous studies the 
cellular signaling pathway of  the gene 
CD82 was discovered to suppress cancer 
tumor metastasis per regulation of  
proteins: c-Met and Src kinases. During 
the studies, CD82 interacted with the 
gene CD151 and was found to have the 
opposite effects on metastasis compared 
to CD82. This pathway could ideally 
be targeted for the use of  drug therapy; 
therefore, the research on this pathway is 
imperative. 
The research focuses on observing 
changes in protein interactions involved 
in metastatic prostate cancer cells: 
CD151’s association with C-met in the 
